VEGFA and renal cell carcinoma: Everolimus, an oral mammalian target of rapamycin inhibitor, has also revealed activity in the treatment of RCC, particularly in patients who developed on earlier treatment with vascular endothelial growth factor (VEGF)–targeted therapy [12].